CURRENT Share Structure
Outstanding Shares 73,832,151 as of 06/20/2018
CVR Medical Corp – Improving Life by Improving Healthcare.
ABOUT CVR MEDICAL CORP:
CVR Medical Corp. is a med-tech organization dedicated to the development and advancement of revolutionary technology at work within the healthcare sector. Specifically, The Carotid Stenotic Scan (CSS), a groundbreaking tool which will be used to assess Carotid Arterial health in a way which is unavailable to the patient, healthcare provider, and the payor within the current system. By leveraging intellectual property, market and industry know-how, and key strategic relationships, CVR Medical has entered into a trajectory which will revolutionize healthcare and dramatically improve clinical outcomes.
1111 West Georgia, 114th fllor
Vancouver, British Columbia
Brisco Capital Partners Corp.
Scott Koyich, President
Phone: (403) 262-9888 LEADERSHIP:
Peter Bakema: CEO
Mr. Bakema has thirty seven year track record of successfully creating and developing businesses from the ground up. He has overseen multiple organizations with a human resource development of several hundred employees and contractors. His extensive background in business management, capitalization, mergers and acquisitions has been combined with years of hands on leadership experience in the medical device arena. This has given him the ability to adapt quickly to an ever changing healthcare sector. As the Chairman and CEO of CVR Global for the last ten years, Mr. Bakema is responsible for the direction of CVR Global with an emphasis on a sound business infrastructure that is capable of rapid scalability and regulatory compliance.
Tony Robinson: Chief Operations Officer
Mr. Robinson is a passionate leader, seasoned by guiding multiple organizations within the medical device field. His experience encompasses management of operational, marketing, regulatory, and financial areas on domestic and global stages, with a specialization in successfully meeting both regulatory and business needs. He has earned a degree from the University of Michigan, as well as an MBA in Healthcare Management. Mr. Robinson has been immersed in the day to day workings of CVR Global Inc. over the past eight years, driving progress and growth across all key clinical and operational functions, with a focus on both the end user acceptance and market commercialization. Previously, Mr. Robinson was responsible for the management of regulatory actives for a recognized global medical device manufacturer, placing over 25,000 SKU’s into the healthcare marketplace. This was preceded by a role with a top tiered clinical care organization as Director of Marketing.
Erwin Wong: CFO & Board Director
Mr. Wong earned his Bachelor’s of Commerce at the University of British Columbia in 1990. After articling with Cooper’s & Lybrand, Mr. Wong attained his Chartered Accountant designation in 1994. Mr. Wong has previously worked as the director of Asian operations for a national institutional brokerage house focused on the small to mid-cap market, and acted as the Vice-President of Finance for a publicly-listed Asian based group with interests in real estate and telecommunications. Mr. Wong has also acted as a director for various Mainland Chinese based enterprises, including a China-based transportation/logistics group and a Hebei Province based chemicals concern.
Ron Birch: Board Director
Mr. Birch has been President of Big Bar Resources Corporation, since November 2008 and served as its Chief Executive Officer until September 2016. Mr. Birch served as President and Chief Executive Officer of Okana Ventures Inc. from May 9, 2005 to June 2008. Mr. Birch has 17 years of experience with the Bank of Nova Scotia in various positions and locations throughout the Province of British Columbia, lastly as Branch Manager in Prince Rupert, B.C. He worked for 7 years as a retail stock broker with CM Oliver & Co., Ltd. and Pacific International Securities Inc. in Vancouver. During this time, Mr. Birch also took courses for Options and Commodities and was successful in completing these courses and obtaining certificates and licenses for each. Mr. Birch has been providing consulting services through Janron Consulting Inc. since 1991 and services of a Public Relations Coordinator through Bircress Corporate Relations since 1993. From 1985 to 1991, he was a licensed Stock, Commodities and Options Broker. He has been a Director of Big Bar Resources Corporation since November 14, 2008. Mr. Birch served as a Director of Okana Ventures Inc. from May 9, 2005 to June 2008 and Jupiter Enterprises Inc. since March 12, 1999.
Jeremy Poirier: Director
Mr. Poirier worked in the Public market space for over 10 years. Mr. Poirier has both raised money for a number of different public companies as well as represented over 30 public companies well owning his own Investor Relations firm. Mr. Poirier obtained courses in both Business Law and Accounting from the University of BCIT. Before joining Pure Energy Minerals Mr. Poirier was working with a number of junior resource stocks including a public Lithium company assisting in bringing Investor Awareness and raising capital. Mr. Poirier has also served on various board and officer positions with several companies in the private sector including a large cosmetic company across Canada.
Paul Blunden, M.D.: Board of Directors - Medical Advisor
Dr. Blunden is a board certified physician in obstetrics and gynecology with over twenty years in practice. Currently acting as the vice president and partner of a large multi-million dollar multi-provider practice servicing urban, suburban and rural patients. He has previously served as a department chairman for a major health system and has been a member of the executive leadership committee focused on fiscal management, quality improvement and recruiting. Mr. Blunden specializes in both Micro and Macro level managerial decision making with an emphasis on patient care and efficient business/medical coalescing.
Vice President of Quality Systems
•20 Years of Quality Know-how
•Former Vice President of Quality for HSBC & Motorola
•Experience in multiple markets including healthcare, defense, public safety, retail, energy, and manufacturin
Dr. W. Douglas Weaver
CVR Global Board of Directors / Scientific Advisory Board
•Past President of the American College of Cardiology
•Former Vice President and System Medical Director of Heart and Vascular Services at Henry Ford Health System
•Over 330 publications, most of which are related to drug and device discovery and methods toward improving the care provided to patients with cardiovascular disease
About CVR Global
CVR Global Inc. is a private C Corporation incorporated in 2007. The Company is dedicated to the commercialization of it’s patented sub-sonic sound analysis technology. The CVR technology offers the potential to non-invasively interpret blood flow within the human body in order to detect anatomical illness. The first application of the technology is a device geared toward the detection and measurement of carotid arterial stenosis. The diagnostic device will potentially provide a cost-effective tool to assess the most direct risk factor for Ischemic Stroke. Additionally, the CVR technology will be used to analyze levels of stenosis in other human arterial systems, along with various other medical and industrial applications. INNOVATION: The CVR Carotid Stenotic Scan (CSS)
The Carotid Stenotic Scan (CSS) is a screening tool designed to detect and measure carotid arterial stenosis or occlusion for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool which complements other stroke screening technology such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), and computed tomography angiography (CTA). CVR’s screening device is non-emissive, non-invasive, does not require a certified technician, can be conducted in a few minutes, and has a per scan price point that is significantly advantageous as an initial screening tool when compared to the resource requirement associated with other technologies.
At what stage of development is the Carotid Stenotic Scan (CSS)?
Currently CVR is entering the Clinical phase of the development process. The final market version of the CSS is being assembled and prepped for Pivotal Trials, which will then be submitted for FDA 510(k) clearance.
CVR’s technology makes a connection between fluid flow and sub-sonic frequencies in order to determine the presence of arterial disease/blockage. The technology, in its present configuration, detects and analyzes the low frequency vibrations that radiate passively from the carotid arteries. Blood flowing through the carotid arteries produces wave patterns which are shaped and altered by the presence of any irregularities on the inner walls of those arteries. The wave patterns are captured and mathematically analyzed through CVR’s patented algorithms which generate an accurate percentage range of stenosis (including 100% stenosis, or complete occlusion). This analysis is then followed by immediate interpretation with details concerning the inner surface of the carotid arteries against which there is blood flow. Shareholder Information
|Shares on Issue: ||73,832,151 |
|Options: ||4,050,000 |
|Warrants ($0.40): ||6,382,949 (Expires September 15, 2018) |
|Warrants ($0.70): ||2,197,591 (Expires August 22, 2018) |
|Warrants ($0.70): ||3,261,120 (Expires October 19, 2018)) |
|Warrants ($0.70): ||830,000 (Expires October 22, 2018) |
|Warrants ($0.70): ||444,600 (Expires February 26, 2019) |
|Warrants ($0.70): ||408,286 (Expires March 6, 2019) |
|Warrants ($0.70): ||107,500 (Expires March 16, 2019) |
|Warrants ($0.70): ||712,823 (Expires March 21, 2019) |
|Warrants ($0.70): ||700,000 (Expires May 02, 2019) |
|Warrants ($0.70): ||855,193 (Expires June 18, 2019) |
|Warrants ($1.50): ||2,518,600 (Expires April 6, 2020) |
|Trading Symbols: ||TSX.V: CVM |
|CUSIP #: ||126632108 |
|ISIN #: ||CA1266321084 |
|Transfer Agents: || |
AST Trust Company (Canada)
1600 – 1066 West Hastings St.
Vancouver, BC V6E 3X1
Tel: 604.235.3701 Fax: 604.235.3705
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, New York 11219, U.S.A
Toll Free: 1.800.937.5449 Tel: 718.921.8124
Email: email@example.com Website: www.amstock.com
|IR Contact: || |
Brisco Capital Partners Corp.
Scott Koyich, President
CVR Intellectual Property Summary & Legal Comment
CVR has instituted a comprehensive IP policy to cover several aspects of the CSS device as it prepares to go to market. The IP includes 1 issued US patent, US 9,101,274. An European Counterpart is pending at the moment that parallels the allowed US case. A continuation-in-part, Application No. 14/803,389 is also pending, with a priority date extending back to June 24, 2010.
In June of 2015, CVR file two applications covering the Yoke, utilized for holding the sensors and positioning on a patient, and methods of quantifying and detecting sounds in the carotid artery. Both applications were converted into PCT applications in June of 2016 and now await conversion into the US and other jurisdictions at the end of 2017. These applications have been assigned to a joint venture, but an exclusive license remains with CVR.
In June of 2016, CVR filed five additional provisional patent applications covering several aspects of the CSS device, including additional methods for detecting blockage in a fluid flow vessel, disposable sensing elements (think of the razor/razor blade model), methods for generating clean data for analysis, methods for detecting sounds and determining stenosis, methods for determining appropriate location for detecting fluid flow in the body, and methods for detecting and ablating stenosis.
In December of 2016, CVR filed an additional provisional application directed towards sensing pods that do not need a yoke, in order to position the sensing pods for determining stenosis.
Finally, in January of 2017, CVR filed two design patents, one directed towards the device cart itself, and the second to a version of the Yoke for positioning sensors on a patient.
A summary of these are included in the attached Excel file. These filings are highly confidential and not to be disseminated without authorization by CVR.
CVR continues to develop and expand its IP portfolio as development continues. It is expected that additional applications will be filed to cover final versions of any product that will go to market. Such protection will include patent, design patent, trademark, trade dress, and copyright, where applicable.
CVR also expects that the several pending provisional applications will be converted into PCT applications and that the pending PCT applications (now assigned to a joint venture), will also be converted in due course. NEWS: